DNB Asset Management AS Takes Position in Rhythm Pharmaceuticals, Inc. $RYTM

DNB Asset Management AS acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,528 shares of the company’s stock, valued at approximately $558,000.

A number of other large investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Rhythm Pharmaceuticals by 39.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock valued at $504,589,000 after buying an additional 1,407,313 shares during the last quarter. Federated Hermes Inc. grew its holdings in shares of Rhythm Pharmaceuticals by 2.5% in the third quarter. Federated Hermes Inc. now owns 1,727,885 shares of the company’s stock valued at $174,499,000 after acquiring an additional 41,391 shares in the last quarter. Westfield Capital Management Co. LP increased its position in shares of Rhythm Pharmaceuticals by 21.5% during the second quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company’s stock valued at $102,966,000 after acquiring an additional 288,376 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Rhythm Pharmaceuticals by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,311,253 shares of the company’s stock worth $82,868,000 after acquiring an additional 24,085 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Rhythm Pharmaceuticals by 51.6% in the third quarter. JPMorgan Chase & Co. now owns 1,188,069 shares of the company’s stock worth $119,983,000 after purchasing an additional 404,510 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Wells Fargo & Company decreased their price target on shares of Rhythm Pharmaceuticals from $145.00 to $136.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 22nd. Zacks Research raised Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Finally, The Goldman Sachs Group boosted their target price on Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the company a “buy” rating in a research note on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Rhythm Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $132.07.

Rhythm Pharmaceuticals Stock Performance

Rhythm Pharmaceuticals stock opened at $91.00 on Thursday. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $45.90 and a fifty-two week high of $122.20. The stock has a market cap of $6.21 billion, a P/E ratio of -29.26 and a beta of 2.06. The firm’s fifty day moving average price is $102.65 and its 200-day moving average price is $103.42.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. The company had revenue of $57.25 million for the quarter, compared to analysts’ expectations of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.Rhythm Pharmaceuticals’s revenue for the quarter was up 36.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.72) EPS. On average, analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Key Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $140, signaling stronger upside expectations from that shop and likely supporting buying interest. Canaccord raises PT to $140
• Neutral Sentiment: H.C. Wainwright reaffirmed a “Buy” stance and set a $110 target, keeping institutional support for the stock even after adjusting assumptions; that helps sentiment but is less bullish than Canaccord’s view. H.C. Wainwright price target cut to $110
• Negative Sentiment: H.C. Wainwright cut near-term EPS forecasts sharply — trimming FY2026 and multiple quarterly estimates and pushing meaningful profitability into 2027 (they still model positive EPS in FY2027). Those downgraded near-term earnings projections increase execution risk and explain some downward pressure/volatility despite the maintained Buy rating.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider directly owned 20,814 shares in the company, valued at approximately $2,310,354. The trade was a 13.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 25,003 shares of company stock valued at $2,589,015. 6.10% of the stock is currently owned by company insiders.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.